Novo Nordisk A/s

Sanquin Blood Supply Foundation

Novo Nordisk Healthcare Ag

Henning Ralf Stennicke

Ole Hvilsted Olsen

Koenraad Mertens

Peder Lisby Noerby

Laust Bruun Johnsen

Kasper Lamberth

Henriet Meems

Johannes Jacobus Voorberg

Alexander Benjamin Meijer

Maartje Van Den Biggelaar

Shawn DeFrees

Lars Thim

Henrik Oestergaard

Thomas Dock Steenstrup

Gert Bolt

Marianne Hjortnes Kjalke

Brian Berg Stidsen Vandahl

Bernd Peschke

Carsten Behrens

Nils Langeland Johansen

Anders Klarskov Petersen

Mikael Kofod-Hansen

Shawn Defrees

Jens Buchardt

Florencio Zaragoza Dörwald

Soeren Oestergaard

Christian Rischel

Marianne Hjortnæs Kjalke

Jens Jacob Hansen

Magali A Zundel

Niels Peter Fiil

Henrik ØStergaard

Eva H Norling Olsen

Binow Brit SØRENSEN

Thomas R Barnett

Tony Pusateri

Brian Berg Vandahl

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.

Factor VIII variants having a decreased cellular uptake

The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.

Factor VII conjugates

The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.

Conjugated factor VIII molecules

A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.

Selective modification of proteins

Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.

Selectively conjugated peptides and methods of making the same

Growing community of inventors

Kokkedal, Denmark

Henning Ralf Stennicke